U.S. BIOSCIENCE ETHYOL DOES NOT DECREASE SURVIVAL RATE
Executive Summary
U.S. BIOSCIENCE ETHYOL DOES NOT DECREASE SURVIVAL RATE in patients with advanced epithelial ovarian cancer, John Click, MD, University of Pennsylvania, told the American Society of Clinical Oncology May 16 in Dallas. Click presented the results of a Phase III trial encompassing 200 ovarian cancer patients comparing treatment with a regimen of the chemoprotective agent Ethyol (amifostine) and the chemotherapy agents cyclophosphamide and cisplatin to treatment with cyclophosphamide and cisplatin alone.